Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ischemic Stroke: Prying Open the Treatment Window

Executive Summary

At this year's International Stroke Conference in San Antonio, some exciting device-based therapies and approaches were discusssed--including advanced imaging, multimodal therapy and stent-like thrombectomy devices--that may offer improved outcomes for patients that suffer an acute ischemic stroke.

You may also be interested in...

Neurointerventional Market Shows Strong Growth Potential

The neurointerventional device market is one of the most dynamic areas in the field of neurology. Over the next four years, US neurointerventional procedures are expected to grow at a rate of nearly 18% compounded annually, reaching more than 197,000 procedures by 2015. The market information in this article was compiled from Medtech Insight’s new report "US Markets for Neurosurgical and Neurointerventional Surgical Products," #A590, published March 2011.

ISC 2011: Stroke Device Innovation and Investment

At this February's International Stroke Conference held in Los Angeles, the latest advances in cerebrovascular disease diagnosis, treatment, and prevention were highlighted, including cutting-edge endovascular therapies for use in acute ischemic stroke treatment and prevention, as well as new options for more deadly hemorrhagic stroke.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover Covidien's acquisition of ev3, J&J's moves in the endovascular market, DePuy's launch of new products in hip revision, and FDA regulation of consumer genomics.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts